Vancouver-based psychedelic extraction and drug discovery company Filament Health has gained FDA approval for two clinical trials investigating the effects of its botanical psilocybin drug candidate, PEX010.
One trial assesses its potential for alleviating cancer-related anxiety in a group therapy model and is conducted at the University of Washington. The other trial examines its synergy with cognitive-behavioral therapy to enhance treatment outcomes for depression and is conducted at UCLA's Semel Institute.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.